AngioDynamics' CEO Eamonn Hobbs Granted Honorary Fellowship by Society of Interventional Radiology
Janette D. Durham, M.D., M.B.A. and president of SIR wrote in her nomination letter, "Eamonn has been dedicated to research and the development of interventional radiology products since his company was founded... Eamonn's commitment to the development of innovative devices for angiography, thrombolytic delivery, and venous disease has furthered the innovative treatment and patient care options for the specialty of IR."
"I am truly honored to be granted this recognition," said Eamonn Hobbs. "The new innovative minimally invasive procedures developed by interventional radiologists have been vital to improving patients' lives. AngioDynamics has had the good fortune to be able to support these new procedures by working in close collaboration with interventional radiologists to develop new medical devices that allow physicians to more easily treat their patients. We will continue to work with SIR members on new ideas for the treatment of peripheral vascular diseases."
The Society of Interventional Radiology is a non-profit, national scientific organization of more than 4000 physicians and allied health professionals committed to improving health and the quality of life through the practice of vascular and interventional radiology. The Society promotes education, research and communication, while providing leadership in the development of healthcare policy.
AngioDynamics, Inc. (www.angiodynamics.com) is a leading provider of products used by interventional radiologists and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease.
The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects", "intends", "anticipates", "plans", "believes", "seeks", "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the outcome of the Diomed patent litigation, the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Form 10-Q for the quarter ended November 27, 2004, and its Annual Report on Form 10-K for the year ended May 29, 2004, may affect the actual results achieved by the Company.
CONTACT: AngioDynamics, Inc. Robert Rossell, (800) 772-6446 x112 www.angiodynamics.com or Investor Relations Contacts: Lippert/Heilshorn & Associates, Inc. Kim Sutton Golodetz, (212) 838-3777 email@example.com Bruce Voss, (310) 691-7100 firstname.lastname@example.org SOURCE: AngioDynamics, Inc.